Replies to post #1836 on Lisata Therapeutics Inc (LSTA)

[James salmon]

Clarification just issued in another filing;


•
Dr. Mazzo states: “[T]he money that this [$17.7 million grant] brings will allow us to advance through Phase III and to bring this therapy to market . . . .” To clarify, use of any of the grant funds from the California Institute for Regenerative Medicine is subject to dollar-for-dollar match funding by the Company. In addition, as disclosed in the Company’s Form 10-Q for the quarterly period ended March 31, 2015, filed with the SEC on May 6, 2015, the Intus Phase 3 study is expected to cost approximately $43 million.


Probably reason why company is looking to raise some money, as they have to match grant dollar for dollar.